From Cancer to COVID, Can AI Help Find the Next Blockbuster Drug?

With millions of protein combinations in the body to consider, drug development is expensive, time consuming and potentially dangerous. AI models can scour the human proteome for new drug components, cutting down development time and cost, and, crucially, limiting harmful side effects. Naheed Kurji, co-founder and CEO of Toronto-based biotech firm Cyclica and AAIH secretary, shares how cloud not only makes this research possible but also enhances collaboration during medical crises like COVID-19.